RBM3 and ovarian carcinoma: Given the previously demonstrated association between RBM3 and cisplatin sensitivity in ovarian cancer cell lines [15], the potential value of RBM3 as a predictor of response to platinum-based chemotherapy in patients with metastatic malignant melanoma could be of interest to investigate in future studies.